Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Incretin mimetics are widely used for type 2 diabetes, enhancing glucose-dependent insulin secretion.
• While short-term benefits are documented, long-term effects on pancreatic beta cell function remain unclear.

Purpose of the Study:

• To investigate the long-term impact of liraglutide, an incretin mimetic, on human pancreatic islet and beta cell function in vivo.
• To assess the consequences of prolonged incretin mimetic therapy on glucose homeostasis.

Main Methods:

• Human pancreatic islets were transplanted into humanized mice.
• Mice received daily liraglutide treatment for over 200 days.
• Insulin release and glucose homeostasis were evaluated.

Main Results:

• Prolonged liraglutide treatment led to compromised human insulin release from transplanted islets.
• Deranged overall glucose homeostasis was observed in treated mice.
• These effects suggest potential adverse outcomes with chronic incretin mimetic use.

Conclusions:

• Long-term incretin mimetic therapy, exemplified by liraglutide, may negatively impact beta cell function and glucose regulation.
• These findings raise concerns regarding the safety of chronic potentiation of beta cell function in type 2 diabetes management.